Dig Dis Sci: 普瑞巴林和抗氧化剂组合疗法在减轻慢性胰腺炎疼痛中的作用

2020-11-21 MedSci原创 MedSci原创

慢性胰腺炎(CP)的特征是胰腺缓慢且不可逆转的损害,其症状包括反复发作的腹痛,疾病加重以及进行性和永久性外分泌或内分泌功能不全。

        慢性胰腺炎(CP)的特征是胰腺缓慢且不可逆转的损害,其症状包括反复发作的腹痛,疾病加重以及进行性和永久性外分泌或内分泌功能不全。大约90%的CP患者出现顽固性复发性腹痛,需要采取积极的治疗方法。多年来,临床医生尝试了多种治疗方式来减轻CP的疼痛。但是,这些当前使用的治疗方式均不能完全有效地为CP患者提供永久且可接受的疼痛缓解。普瑞巴林疗法与抗氧化剂联合使用据报道是有用的。因此,进行了这项研究以确定抗氧化剂和普瑞巴林疗法的组合在减轻CP患者疼痛中的功效。

 

         本项研究是一项前瞻性,双盲随机试验。治疗组接受普瑞巴林抗氧化剂治疗8周,并向对照组给予类似的安慰剂。主要观察结果是确定通过视觉模拟量表(VAS)和Izbicki疼痛评分评估的最大疼痛强度的变化。次要观察结果是痛苦的天数,阿片类药物和非阿片类药物的需求量,生活质量的改善,入院次数以及患者的总体满意度。

 

 

        总共90名患者被随机分为2组,每组45名。人口统计学特征和基线疼痛评分在基线时相似。与安慰剂组相比,治疗组患者的疼痛强度显着降低(VAS评分2±0.8 vs. 1.3±0.9;p  = 0.007),非阿片类镇痛需要天数(54.4±2.9 vs. 55.7±1.5;p  = 0.014)和住院人数(0.2±0.5和0.6±0.7;p  = 0.002)也有明显下降。与安慰剂组相比,治疗组满足的患者比例显着增加(18%vs. 11%;p  = 0.03)。

 

 

        本项研究证明了普瑞巴林和抗氧化剂的组合可显着减轻CP患者的疼痛,减少非阿片类镇痛药的需求以及住院天数,它还可以显着提高整体患者满意度。

 

 

 

原始出处:

Sathasivam Sureshkumar. Et al. Efficacy of Pregabalin and Antioxidants Combination in Reducing Pain in Chronic Pancreatitis: A Double Blind Randomized Trial. Digestive Diseases and Sciences.2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1773070, encodeId=9e171e730703a, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Mon Jan 18 19:41:44 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949389, encodeId=ecc8194938912, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Sep 28 07:41:44 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013534, encodeId=259a2013534a2, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Feb 21 15:41:44 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901862, encodeId=ca9a90186254, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66365438100, createdName=ms3000001712621089, createdTime=Tue Nov 24 18:19:00 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310312, encodeId=6cab1310312ab, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Nov 23 03:41:44 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489365, encodeId=cd65148936587, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Mon Nov 23 03:41:44 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900976, encodeId=b3c39009e6c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ef5229698, createdName=1479a088m25暂无昵称, createdTime=Sat Nov 21 12:45:37 CST 2020, time=2020-11-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1773070, encodeId=9e171e730703a, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Mon Jan 18 19:41:44 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949389, encodeId=ecc8194938912, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Sep 28 07:41:44 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013534, encodeId=259a2013534a2, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Feb 21 15:41:44 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901862, encodeId=ca9a90186254, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66365438100, createdName=ms3000001712621089, createdTime=Tue Nov 24 18:19:00 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310312, encodeId=6cab1310312ab, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Nov 23 03:41:44 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489365, encodeId=cd65148936587, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Mon Nov 23 03:41:44 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900976, encodeId=b3c39009e6c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ef5229698, createdName=1479a088m25暂无昵称, createdTime=Sat Nov 21 12:45:37 CST 2020, time=2020-11-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1773070, encodeId=9e171e730703a, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Mon Jan 18 19:41:44 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949389, encodeId=ecc8194938912, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Sep 28 07:41:44 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013534, encodeId=259a2013534a2, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Feb 21 15:41:44 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901862, encodeId=ca9a90186254, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66365438100, createdName=ms3000001712621089, createdTime=Tue Nov 24 18:19:00 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310312, encodeId=6cab1310312ab, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Nov 23 03:41:44 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489365, encodeId=cd65148936587, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Mon Nov 23 03:41:44 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900976, encodeId=b3c39009e6c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ef5229698, createdName=1479a088m25暂无昵称, createdTime=Sat Nov 21 12:45:37 CST 2020, time=2020-11-21, status=1, ipAttribution=)]
    2021-02-21 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1773070, encodeId=9e171e730703a, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Mon Jan 18 19:41:44 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949389, encodeId=ecc8194938912, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Sep 28 07:41:44 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013534, encodeId=259a2013534a2, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Feb 21 15:41:44 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901862, encodeId=ca9a90186254, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66365438100, createdName=ms3000001712621089, createdTime=Tue Nov 24 18:19:00 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310312, encodeId=6cab1310312ab, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Nov 23 03:41:44 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489365, encodeId=cd65148936587, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Mon Nov 23 03:41:44 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900976, encodeId=b3c39009e6c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ef5229698, createdName=1479a088m25暂无昵称, createdTime=Sat Nov 21 12:45:37 CST 2020, time=2020-11-21, status=1, ipAttribution=)]
    2020-11-24 ms3000001712621089

    good

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1773070, encodeId=9e171e730703a, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Mon Jan 18 19:41:44 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949389, encodeId=ecc8194938912, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Sep 28 07:41:44 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013534, encodeId=259a2013534a2, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Feb 21 15:41:44 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901862, encodeId=ca9a90186254, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66365438100, createdName=ms3000001712621089, createdTime=Tue Nov 24 18:19:00 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310312, encodeId=6cab1310312ab, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Nov 23 03:41:44 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489365, encodeId=cd65148936587, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Mon Nov 23 03:41:44 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900976, encodeId=b3c39009e6c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ef5229698, createdName=1479a088m25暂无昵称, createdTime=Sat Nov 21 12:45:37 CST 2020, time=2020-11-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1773070, encodeId=9e171e730703a, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Mon Jan 18 19:41:44 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949389, encodeId=ecc8194938912, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Sep 28 07:41:44 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013534, encodeId=259a2013534a2, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Feb 21 15:41:44 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901862, encodeId=ca9a90186254, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66365438100, createdName=ms3000001712621089, createdTime=Tue Nov 24 18:19:00 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310312, encodeId=6cab1310312ab, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Nov 23 03:41:44 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489365, encodeId=cd65148936587, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Mon Nov 23 03:41:44 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900976, encodeId=b3c39009e6c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ef5229698, createdName=1479a088m25暂无昵称, createdTime=Sat Nov 21 12:45:37 CST 2020, time=2020-11-21, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1773070, encodeId=9e171e730703a, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77638, encryptionId=38b7e76380a, topicName=组合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81db38453761, createdName=yankaienglish, createdTime=Mon Jan 18 19:41:44 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949389, encodeId=ecc8194938912, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Sep 28 07:41:44 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013534, encodeId=259a2013534a2, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Feb 21 15:41:44 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901862, encodeId=ca9a90186254, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66365438100, createdName=ms3000001712621089, createdTime=Tue Nov 24 18:19:00 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310312, encodeId=6cab1310312ab, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Nov 23 03:41:44 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489365, encodeId=cd65148936587, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Mon Nov 23 03:41:44 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900976, encodeId=b3c39009e6c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ef5229698, createdName=1479a088m25暂无昵称, createdTime=Sat Nov 21 12:45:37 CST 2020, time=2020-11-21, status=1, ipAttribution=)]
    2020-11-21 1479a088m25暂无昵称

    学习了

    0

相关资讯

JNNP:遗传额颞叶痴呆中C9orf72基因携带者的丘脑-皮质-纹状体萎缩与疼痛觉异常有关

额颞叶痴呆(FTD)是一种复杂的神经退行性疾病,涵盖一系列症状。行为异常,语言功能障碍,认知缺陷和运动障碍综合形成了FTD的典型症状,但据报道,许多其他症状也经常被忽略,包括疼痛感的改变。一研究的论文

J Clin Nurs:与机器人互动可改善痴呆患者的慢性疼痛

研究已证实机器人海豹PARO可以改善痴呆症患者的情绪和急性疼痛。本研究旨在探究与与PARO互动是否可改善痴呆症患者的慢性疼痛。

Arch Phys Med Rehabil:疼痛学教育和锻炼可改善患者多方面的生活质量

本研究旨在探究与常规护理相比慢性疼痛自我管理支持与疼痛科学教育和锻炼(COMMENCE)在改善功能、疼痛干扰、工作状态、疼痛强度、疲劳、与疼痛相关的心理因素、健康护理访问、满意度和感知变化方面的有效性

Pain Res Manag:腹腔神经节术中化学脾切除术对可切除的胰腺或胃肿块患者的止痛效果

胰腺和胃肿块切除术中化学性脾切除术的试验,导致患者术后疼痛有明显差异。本研究旨在确定酒精神经切断术是否能缓解胃切除术和Whipple手术后的术后疼痛,探讨了术后前四个月的结果差异。

癌症晚期有多痛?专家在体内装上这个“黑科技”,成为疼痛新“克星”

癌痛是癌症病人尤其是晚期患者较为常见的一个症状。癌痛与一些慢性疼痛不一样,它很少有间歇期,癌症一旦进展,疼痛感会越来越重,组织损伤的程度也越来越严重。而且癌痛还可能产生或者加重许多躯体症状。

病人疼痛是正常,必须忍?专家说熬不过疼痛而轻生的患者都错了!

严峻的现实是,随着人口老龄化、不良的生活习惯和行为、慢性疾病人数的暴增,导致慢性疼痛的患者越来越多。